Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets

Published by: Datamonitor

Published: May. 19, 2009 - 264 Pages


Table of Contents


ABOUT DATAMONITOR HEALTHCARE
About the Infectious diseases pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor insight into the vaccine delivery technologies market
Related reports
Upcoming related reports
CHAPTER 2 ANTIGEN TYPES FOR HUMAN VACCINES
Historic overview of antigen development for vaccines
Live-attenuated pathogens
Inactivated/killed pathogens
Protein-based subunit or toxoid vaccines
Polysaccharide subunit vaccines
DNA/RNA vaccines
CHAPTER 3 RATIONALE FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY SYSTEMS
Novel delivery vehicles could improve the efficacy of subunit vaccines
Improved antigen stability is a key need, particularly for mucosal administration routes
Delivery vehicles with additional adjuvant qualities could enable the development of vaccines against challenging indications
CHAPTER 4 CHALLENGES FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY VEHICLES
Cost containment could become a key hurdle for novel vaccine delivery vehicles
More research is needed to understand the molecular mechanisms of antigen delivery
The conservative attitude of regulators towards novel adjuvants and delivery vehicles is a key challenge
Various new technologies are in development as antigen delivery vehicles
CHAPTER 5 BACTERIAL/VIRAL VECTORS
Summary
General considerations
Bacterial/viral vector vaccines in development
Acambis/Sanofi Pasteur - ChimeriVax technology
Crucell - Advax technology
Bavarian Nordic - MVA-BN
Datamonitor assessment
CHAPTER 6 LIPOSOMES
Summary
General considerations
Liposomal vaccines in development
Merck Serono - Stimuvax/L-BLP25
NasVax - VaxiSome technology
Datamonitor assessment
CHAPTER 7 VIROSOMES
Summary
General considerations
Marketed and pipeline virosomal vaccines
Crucell - Immunopotentiating reconstituted influenza virosome (IRIV) technology
Pevion Biotech - PeviPro and PeviTer virosome technologies
Datamonitor assessment
CHAPTER 8 VIRUS-LIKE PARTICLES
Summary
General considerations
Marketed and pipeline VLP vaccines
Cytos Biotechnology - Immunodrug platform
Novavax - baculovirus-based VLPs
Others
Datamonitor assessment
CHAPTER 9 ISCOM/ISCOMATRIX
Summary
General considerations
ISCOM/ISCOMATRIX-based vaccines in development
CSL and licensees - ISCOMATRIX
Datamonitor assessment
CHAPTER 10 MICROPARTICLES/NANOPARTICLES
Summary
General considerations
Micro-/nanoparticle technologies in development for vaccines
PLGA - poly(-lactide co-glycolide)
Chitosan
Datamonitor assessment
BIBLIOGRAPHY
Literature
APPENDIX
Contributing experts
Academic key opinion leaders
Industry key opinion leaders
Conferences
Report methodology
About Datamonitor
About Datamonitor Healthcare
About the Infectious Diseases analysis team
Key therapy team members
Holger Rovini, Head of Respiratory and Infectious Diseases
Hedwig Kresse, Senior Analyst, Infectious Diseases
Disclaimer
List of Tables
Table 1: Key marketed live-attenuated vaccines, 7MM, May 2009
Table 2: Summary of key antigen delivery technologies in development
Table 3: Viral and bacterial vector-based vaccines for prophylactic vaccine applications, May 2009
Table 4: Viral and bacterial vector-based vaccines for therapeutic vaccine applications, May 2009
Table 5: SWOT analysis: bacterial/viral vector based vaccine delivery
Table 6: Key pipeline liposomal vaccines
Table 7: SWOT analysis - liposome-based vaccine delivery
Table 8: Key marketed and pipeline virosomal vaccines
Table 9: SWOT analysis - virosome-based vaccine delivery
Table 10: Key marketed and pipeline virus-like particle (VLP)-based vaccines
Table 11: SWOT analysis - virus-like particle (VLP)-based vaccine delivery
Table 12: Key pipeline vaccines based on ISCOMATRIX
Table 13: SWOT analysis - ISCOM/ISCOMATRIX-based vaccine delivery
Table 14: Key micro- and nanoparticle technologies in development
Table 15: SWOT analysis - microparticle-/nanoparticle-based vaccine delivery
List of Figures
Figure 1: History of vaccine antigen design and delivery
Figure 2: Unmet needs in antigen delivery
Figure 3: Drivers and resistors for the development of antigen delivery vehicles
Figure 4: Public sector immunization cost per child in the US ($), 1975-2008
Figure 5: Vector vaccines
Figure 6: Liposomal vaccine delivery
Figure 7: Virosome structure
Figure 8: Production of virus-like particles (VLPs)

Abstract

As a result of the increasing switch from live-attenuated and killed whole-cell vaccines to subunit antigens, there is a need for novel antigen delivery technologies to improve vaccine efficacy and safety. This report assesses key strategies, technologies and products for vaccine antigen delivery. It provides an overview of opportunities and challenges for the sector and a future outlook.

Scope
  • In-depth analysis of key vaccine antigen delivery technologies
  • Thorough assessment of the potential for selected vaccine antigen delivery technologies
  • Review of industry and academic stakeholder opinions involved in the vaccine antigen delivery sector
  • In-depth discussion of key opportunities and risks for novel vaccine antigen delivery technologies
Highlights

There is a significant need for novel vaccine antigen delivery technologies following the increasing switch from live-attenuated and killed whole-cell vaccines to subunit antigens. Key drivers for the sector are the need for increased immunogenicity and safety as well as for vaccine formulations combining delivery systems and adjuvant.

Virus-like particles and virosomes, both benefiting from the successful track record of already marketed vaccines, have the best potential in the short- to mid term. ISCOM-based technologies could be valuable for therapeutic vaccines, while liposomes and micro-/nanoparticles will not play a major role for vaccine delivery in the foreseeable future.

Antigen stability, safety and immunogenicity are the key hurdles for novel antigen delivery technologies. In times of restricted healthcare budgets, pricing and manufacturing costs need to be kept to a minimum. The limited understanding of the detailed molecular mechanisms for many technologies poses a further challenge.

Reasons to Purchase

Review profiles of key vaccine antigen delivery technologies both marketed and in clinical development and assess their future potential

Gain insight into the current state of vaccine antigen delivery technologies and their future opportunities and challenges

Benefit from opinions of key industry and academic stakeholders in the vaccine antigen delivery field

Please note: this is delivered as a Zip file.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009